AbbVie Ordered To Pay $150 Mln In AndroGel Lawsuit – Markets Insider

(RTTNews) – A federal jury in Chicago ordered AbbVie Inc. (ABBV) to pay $150 million in punitive damages to an Oregon man after finding the company liable for fraudulent misrepresentations about the safety of the testosterone-replacement therapy AndroGel.

“This is a great result for the Mitchell family and all the other victims of AbbVie’s fraudulent conduct. Today, this jury sent a clear message. AbbVie, hopefully, hears it,” said MDL co-lead counsel Chris Seeger.

Mitchell is one of more than 4,000 plaintiffs who have sued AbbVie Inc. in the federal multidistrict litigation, In re: Testosterone Replacement Therapy Products Liability Litigation, before Judge Matthew Kennelly in the U.S. District Court for the Northern District of Illinois.

Mitchell claimed that AbbVie fraudulently misled doctors and patients about the drug’s benefits and risks—in particular, cardiovascular risks—when marketing the drug. The jury deliberated for 4 hours before reaching its verdict.  Partner Dave Buchanan, a member of the Mitchell trial team, commented, “For years before Jesse took AndroGel, AbbVie promoted unproven benefits and falsely assured doctors and patients about the safety of the drug.  The consequences of those acts are serious and real—facts that weren’t lost on this jury.

This Article Was Originally From *This Site*

Powered by WPeMatico